Fact-checked by Grok 2 weeks ago

Cyanopsia

Cyanopsia, also known as vision or cyanopia, is a rare visual disorder characterized by the perception of a or cyan tint across the entire , causing all objects to appear bluish in color. This condition falls under the broader category of chromatopsia, where an abnormal hue dominates , and it most commonly affects older adults or individuals using specific medications. The primary causes of cyanopsia include postoperative effects following and side effects from certain pharmaceuticals. After extraction, the removal of the clouded, yellowed natural lens—replaced by a clear (IOL)—allows increased transmission of short-wavelength to the , overwhelming the blue-sensitive cones and producing the tint. Pharmacologically, it is frequently linked to phosphodiesterase-5 (PDE5) inhibitors such as (Viagra), which cross-react with PDE6 enzymes in retinal cone cells, disrupting phototransduction and favoring perception; other implicated drugs include and . Less common triggers involve toxicity or lack of filtering in IOLs. Cyanopsia gained notable public attention in the late 1990s with the introduction of for , as clinical trials and post-marketing reports documented transient blue-tinted vision in up to 3-11% of users, often resolving within hours but occasionally persisting longer. In the context of , the phenomenon remains temporary in the vast majority of cases, with recalibrating color perception over days to weeks via mechanisms in the . Although usually benign and self-limiting, persistent cyanopsia may require evaluation for underlying damage or IOL adjustment, emphasizing the importance of blue-light-filtering IOLs in modern surgical practice to mitigate risks.

Clinical Presentation

Signs and Symptoms

Cyanopsia manifests as a persistent tint across the entire , giving objects a bluish hue that alters normal color perception. Patients often describe this as seeing the world through a filter, affecting both central and uniformly. Associated symptoms may include , increased sensitivity to light (), and occasional mild headaches, particularly when the condition is induced by medications such as . These effects can compound the visual distortion, making it challenging to discern fine details or adjust to varying light conditions. The symptoms of cyanopsia typically resolve spontaneously, lasting from a few hours to several weeks depending on the underlying trigger, with most cases post-cataract surgery improving within days as the adapts. In rarer instances, such as with certain implants, persistence beyond weeks has been reported. This altered color perception can significantly impact daily activities, such as difficulty in reading printed materials where text appears washed out in blue tones, or challenges in due to impaired of signals and . Historical patient reports following frequently describe the experience as entering a "blue world," with early accounts noting the sudden shift to vivid upon removal, as documented in mid-20th-century ophthalmic literature.

Diagnosis

of cyanopsia begins with a thorough patient , emphasizing recent intraocular surgeries such as extraction or exposure to medications known to induce transient color vision changes, including phosphodiesterase-5 inhibitors like . This step is crucial for identifying potential triggers, as cyanopsia is predominantly a subjective complaint without structural abnormalities. A comprehensive ophthalmic examination follows to exclude underlying . Visual acuity assessment, slit-lamp biomicroscopy to evaluate the anterior segment, and funduscopy to inspect the and are standard, typically revealing normal findings in isolated cyanopsia cases. testing, such as pseudoisochromatic plates (e.g., Hardy-Rand-Rittler) or arrangement tests like the Farnsworth Panel D-15, may demonstrate a selective blue-yellow axis shift, confirming the perceived tint. Specialized subjective methods, including achromatic-point settings or neutralization techniques with chromatic plates, can quantify the degree of cyanopsia, particularly in postoperative settings. If initial evaluations suggest retinal or photoreceptor involvement, advanced imaging such as optical coherence tomography (OCT) is employed to assess macular and retinal layer integrity, while electroretinography (ERG) evaluates cone function for any subtle dysfunction. These tests are generally normal in typical cyanopsia but help differentiate it from structural disorders. Differential diagnosis considers conditions mimicking color distortion, such as optic neuropathy (often red-green defects with relative afferent pupillary defect), glaucoma (progressive tritan-like losses), or retinal detachment (accompanied by floaters and vision loss). Cyanopsia is confirmed when symptoms are transient (resolving within days to weeks), non-progressive, and correlated with a clear inciting event, with no evidence of ongoing pathology on examination.

Etiology and Pathophysiology

Causes

Cyanopsia most commonly arises following , where the implantation of synthetic intraocular lenses (IOLs) allows greater transmission of short-wavelength to the compared to the natural crystalline , which absorbs much of this . This effect was first noted in the early with the introduction of ultraviolet-absorbing IOLs, which lacked blue-light filtration and led to altered color perception in patients. Studies indicate that approximately 14% of patients experience cyanopsia two weeks postoperatively with clear-tinted IOLs, though the incidence is significantly lower with blue-filtering IOLs. Medication-induced cyanopsia is another primary trigger, particularly from phosphodiesterase-5 (PDE5) inhibitors such as (Viagra), which inhibit retinal PDE6 enzymes and disrupt normal phototransduction, leading to temporary blue-tinted vision in 3-11% of users at standard doses. Other implicated drugs include (with toxicity associated with cyanopsia alongside other color vision disturbances like , as documented in case reports of patients with elevated serum levels), , and certain antibiotics like ethambutol. Rare causes include (TURP) syndrome, where absorption of irrigant during surgery can produce vision as a novel neurological symptom, as reported in isolated cases. Additionally, unilateral compressive may present with transient cyanopsia as an early indicator, preceding more severe loss. These triggers result in a characteristic tint to the .

Pathophysiology

Cyanopsia arises from disruptions in the visual system's processing of color, primarily involving an imbalance in the stimulation of photoreceptors sensitive to short wavelengths, leading to a perceived blue tint in . In the , short-wavelength-sensitive (SWS) cones, which are tuned to around 420-440 nm, become relatively overstimulated when there is an abrupt increase in transmission to the posterior segment of the eye. This overstimulation occurs because the natural crystalline in older adults progressively absorbs more short-wavelength light due to yellowing and formation, reducing exposure; upon removal and replacement with a clear (IOL), the filtration is lost, allowing unaccustomed levels of to reach the SWS cones and skew color toward . Certain medications, particularly phosphodiesterase type 5 (PDE5) inhibitors like , contribute to cyanopsia through inhibition of type 6 (PDE6), a key enzyme in phototransduction localized to and photoreceptors. PDE6 normally hydrolyzes (cGMP) to terminate the phototransduction cascade; inhibition elevates cGMP levels, prolonging the opening of cyclic nucleotide-gated (CNG) channels and disrupting calcium in photoreceptors. This leads to abnormal signaling from cones, with a preferential effect on blue-sensitive pathways due to the distribution of PDE6 isoforms, resulting in transient cyanopsia that typically resolves as drug levels decline. At higher visual processing levels, the brain undergoes to compensate for the retinal imbalance, recalibrating through mechanisms in the . This adaptation involves shifts in the achromatic point in , where the perceived neutral white adjusts to account for excess input, occurring over several hours with a that stabilizes within about 12 hours post-onset. Such processes help mitigate the temporary color distortion but can prolong symptoms if the initial imbalance is severe. The choice of IOL material influences the degree of blue light transmission and thus the risk of cyanopsia; for instance, clear hydrophobic IOLs transmit higher levels of short-wavelength compared to silicone-based or yellow-tinted acrylic variants that incorporate blue-light-filtering chromophores mimicking the natural . IOLs without filters, such as certain AcrySof models, allow greater penetration, exacerbating SWS cone overstimulation, while IOLs may exhibit slightly different refractive indices but generally similar transmission profiles unless modified. In rare cases, compressive lesions affecting the can precipitate cyanopsia through mechanical disruption of axonal transmission, particularly in the early stages of , leading to unilateral transient blue-tinted vision before progression to dimness or field loss.

Management and Prognosis

Treatment and Management

The primary approach to managing cyanopsia involves , as the condition is typically transient and resolves spontaneously without specific intervention. In cases following , symptoms such as the blue-tinted vision often diminish within days to weeks through to the intraocular lens (IOL), with patient education and reassurance forming the cornerstone of care. For cyanopsia induced by medications, such as phosphodiesterase-5 (PDE5) inhibitors like , prompt discontinuation of the offending agent is recommended, leading to resolution within hours to days in most instances. Similarly, if associated with other drugs like , withdrawal of the medication results in reversal of symptoms. In persistent cases linked to IOL implantation, particularly with non-blue-light-filtering lenses, surgical adjustment through IOL exchange may be considered to alleviate ongoing symptoms. Supportive strategies can include environmental modifications to reduce exposure to bright or blue-enriched lighting, which may exacerbate the perceived tint. Ophthalmology guidelines prioritize conservative management over aggressive treatments, reserving interventions for scenarios with complicating underlying conditions.

Prognosis

Cyanopsia exhibits a high resolution rate, with the majority of cases resolving spontaneously within 1-3 weeks following the inciting trigger. In instances related to and (IOL) implantation, the blue tint typically diminishes as the adapts to the altered light transmission, often fading within days to several weeks. For drug-induced cases, such as those associated with , symptoms are generally shorter-lived, lasting from hours to a few days, though rare instances may persist up to 21 days before full resolution. Persistence beyond one month is uncommon and may signal underlying issues, such as IOL-related complications in surgical patients, warranting further evaluation. There is no documented evidence of cyanopsia leading to permanent vision loss or evolving into visual disorders, underscoring its transient and self-limiting nature. The duration of cyanopsia can vary based on factors including the trigger type, with pharmacological causes tending to resolve more rapidly than postoperative ones due to the absence of structural needs. age may influence recovery, as older individuals, who comprise most surgical cases, often experience slightly prolonged adaptation periods owing to age-related neural changes in color processing. In surgical contexts, follow-up is recommended for 3-6 months to track symptom and detect any rare persistent effects. Brief reference to as a approach supports this expectant outlook, with reserved for non-resolving cases.

Epidemiology and Research

Epidemiology

Cyanopsia is a rare visual disturbance, with its overall incidence closely tied to the prevalence of and use of type 5 (PDE5) inhibitors. Transient cases occur in approximately 14% of patients receiving non-tinted intraocular lenses (IOLs) two weeks post-surgery, resolving by three months in nearly all instances. The condition predominantly affects older adults over 60 years, reflecting the age-related increase in prevalence and subsequent surgical interventions, where rates rise sharply in this demographic. Among medication-related cases, cyanopsia shows a skew toward males due to the primary use of PDE5 inhibitors like for ; reported incidences range from 3% with 25 mg doses to 11% with 100 mg doses. Trends in cyanopsia align with broader medical patterns since the , including a 6.5-fold increase in age- and sex-adjusted rates in the United States from 1988–1990 to 2008–2010, driven by advancements in IOL technology and surgical accessibility. Similarly, the introduction and widespread adoption of PDE5 inhibitors starting with in 1998 have contributed to rising non-surgical cases. Epidemiological data remain limited, with notable gaps such as potential underreporting of transient non-surgical cases, which may go unrecognized due to their mild and self-resolving nature.

Research Directions

Ongoing research into cyanopsia focuses on elucidating its underlying mechanisms, particularly in drug-induced cases. A 2020 case series in Frontiers in Neurology examined 17 patients who experienced persistent ocular side effects from 100 mg sildenafil, including cyanopsia lasting beyond 24 hours, attributed to prolonged inhibition of phosphodiesterase type 6 in retinal photoreceptors. This study highlighted dose-dependent variability in symptom duration, with some patients reporting resolution within days while others required weeks, suggesting individual differences in drug metabolism influence severity. Recent case reports have advanced understanding of cyanopsia in postoperative settings. In a report published in the Indian Journal of Ophthalmology: Case Reports, a 79-year-old developed persistent cyanopsia following implantation of a non-diffractive extended depth-of-focus (IOL), linked to altered transmission, lasting several weeks until resolved by exchanging the IOL for a yellow-tinted version. Such cases underscore the role of IOL in prolonging symptoms, prompting further investigation into light filtration properties. Exploration of variability factors reveals that not all patients exposed to common triggers develop cyanopsia, with IOL type emerging as a key determinant. Short-wavelength light-absorbing IOLs have been shown to significantly reduce early postoperative cyanopsia incidence compared to ultraviolet-only filtering lenses, as demonstrated in a 2015 randomized trial where rates dropped from 14.5% to 4.9% at one month. Patient-specific factors, such as preoperative status and adaptation capacity, are also under study to predict susceptibility. Emerging research targets IOL material innovations to mitigate cyanopsia risk. Blue-light filtering IOLs, which mimic the natural crystalline by absorbing and short blue wavelengths, have been developed to minimize color shifts while preserving , with clinical evidence supporting reduced dysphotopsia and tint complaints in pseudophakic patients. Ongoing trials evaluate hybrid materials that balance correction with minimal blue tint induction. Notable case studies illustrate rare presentations advancing diagnostic insights. A 2018 report in Neurological Sciences described unilateral transient cyanopsia as an initial symptom of compressive in a with a sellar mass, resolved after tumor , highlighting its potential as an early unilateral indicator of neurological compression. Similarly, a 2018 case in A&A Practice documented cyanopsia associated with transurethral resection of the prostate (TURP) syndrome due to irrigation toxicity and , marking the first such report and emphasizing metabolic triggers in vision disturbances.

References

  1. [1]
    Cyanopsia - Oxford Reference
    Quick Reference. n. a condition in which everything looks bluish. From: cyanopsia in Concise Medical Dictionary »Missing: definition | Show results with:definition
  2. [2]
    cyanopia, cyanopsia | Taber's Medical Dictionary
    Vision in which all objects appear to be blue.Missing: definition | Show results with:definition
  3. [3]
    definition of cyanopsia by Medical dictionary
    A condition in which all objects appear blue; may temporarily follow cataract extraction. Synonym(s): blue vision, cyanopia. [cyano- + G. opsis, vision]. Farlex ...
  4. [4]
    Chromatopsia - EyeWiki
    Jan 27, 2025 · Chromatopsia (ie, “see color”) is an uncommon condition in which a patient experiences an increased perception of an environmental hue, leading to color-tinged ...
  5. [5]
    Other Eye Symptoms - Eye Disorders - Merck Manuals
    Certain conditions may cause a blue tint to the visual field (cyanopsia), such as cataract removal or use of phosphodiesterase-5 (PDEF5) inhibitors (eg ...
  6. [6]
    Evaluation of early state of cyanopsia with subjective color settings ...
    Some cataract patients suffer from bluish appearance of overall visual field immediately after cataract removal surgery [1, 2, 3]. This phenomenon is called ...
  7. [7]
    Blue-blocking intraocular implants should be used routinely during ...
    Sep 7, 2012 · Blue-blocking IOLs more closely mimic the young crystalline lens, limiting that additional increase in blue-light transmission postoperatively.
  8. [8]
    Color Vision - EyeWiki
    Jan 6, 2025 · Medication side effects which cause changes in color vision include sildenafil, digoxin, and medications which are toxic to the optic nerve.<|control11|><|separator|>
  9. [9]
    Cyanopsia – Knowledge and References - Taylor & Francis
    Cyanopsia is a visual condition characterized by a blue tint in vision, caused by the inhibition of cone phosphodiesterase enzymes.Missing: treatment - | Show results with:treatment -
  10. [10]
    Visual Side Effects Linked to Sildenafil Consumption: An Update
    Slight incidence (<7%) of chromatopsia, cyanopsia, photophobia, and visual disturbances after administration of 80 mg of sildenafil three times daily were ...
  11. [11]
    List of Drugs that may cause 'Cyanopsia' - Medindia
    This page lists all known medications that could potentially lead to 'Cyanopsia' as a side effect. It's important to note that mild side effects are quite ...
  12. [12]
    Men who took erectile-dysfunction drug had blue-tinted vision for days.
    Feb 7, 2020 · The problems reported included blurred vision, sensitivity to light, reduced eyesight and changes to color perception, including "intensely blue ...Missing: symptoms | Show results with:symptoms
  13. [13]
    Evaluation of early state of cyanopsia with subjective color settings ...
    The result of fitting suggests that color appearance is recalibrated during cyanopsia by some neural mechanisms with a time constant of several hours. It also ...
  14. [14]
    Persistent cyanopsia following non-diffractive extended depth-of ...
    This phenomenon, known as cyanopsia, is primarily due to sudden changes in transmission of light resulting from the switch of the aged crystalline lens in its ...
  15. [15]
    Ocular Side Effects of Sildenafil That Persist Beyond 24 h—A Case ...
    Feb 6, 2020 · Acute secondary effects of sildenafil include headache, heartburn, skin flush, and vision changes such as blurred vision, photophobia, and cyanopsia.
  16. [16]
    Ocular Side Effects of Sildenafil That Persist Beyond 24 h—A Case ...
    Feb 7, 2020 · Regarding the symptom of cyanopsia, the affected patients reported very intensely blue- colored vision with red-green color blindness (i.e., ...
  17. [17]
    Dyschromatopsia following cataract surgery - PubMed
    Although a transient blue discoloration (cyanopsia) might be expected following cataract surgery, an erythropsia (red vision) is more common.
  18. [18]
    Phosphodiesterase inhibitors and the eye - PubMed
    Phosphodiesterase inhibitors and the eye. Clin Exp Ophthalmol. 2009 Jul;37(5): ... Authors. Nathan M Kerr , Helen V Danesh-Meyer. Affiliation. 1 Department ...
  19. [19]
    Neutralization method for detecting the incidence of color perception ...
    Conclusion: The incidence of cyanopsia evaluated with the neutralization method was higher with clear IOLs than with yellow IOLs. In monocular implantation, ...<|control11|><|separator|>
  20. [20]
    Acquired color vision and visual field defects in patients with ocular ...
    There are many forms of color vision deficiencies, mainly affecting the red–green stimuli, blue–yellow stimuli, or randomly distributed in the chromatic cycle.
  21. [21]
    On Seeing Yellow: The Case for, and Against, Short-Wavelength ...
    Jul 11, 2012 · Short-wavelength light–absorbing IOLs appear to reduce the incidence of cyanopsia significantly in the early postoperative period, although ...
  22. [22]
    Ultraviolet or blue-filtering intraocular lenses: what is the evidence?
    Jan 8, 2016 · Historically, the impetus to develop BFIOLs was to reduce chromatic aberration, and cyanopsia, where the recipient of the IOL notices a blue ...
  23. [23]
    Spectrum of digoxin-induced ocular toxicity: a case report and ...
    Aug 23, 2015 · ... xanthopsia (yellow vision), cyanopsia (blue vision) and chloropsia (green vision). Dyschromatopsia can be asymptomatic and revealed only by ...
  24. [24]
    Blue Vision (Cyanopsia) Associated With TURP Syndrome: A Case ...
    Nov 15, 2018 · Here, we report blue vision (cyanopsia), which has never been reported as a symptom of TURP syndrome.
  25. [25]
    Unilateral Transient Cyanopsia as an Early Symptom of ... - PubMed
    Unilateral Transient Cyanopsia as an Early Symptom of Compressive Optic Neuropathy.
  26. [26]
  27. [27]
  28. [28]
    Basic Science of Intraocular Lens Materials - IntechOpen
    Implantation of a UV absorbing IOL results in cyanopsia ... Dual drug delivery from intraocular lens material for prophylaxis of endophthalmitis in cataract ...
  29. [29]
    A Step-by-Step Guide to Cataract Post-op Care - Review of Optometry
    Dec 15, 2021 · The management of such symptoms mostly consists of education and reassurance that the visual disturbances will disappear on their own; however, ...
  30. [30]
    Seeing blue vision after cataract surgery? - Dr Agarwals Eye Hospital
    Aug 6, 2025 · This blue haze is typically a temporary side effect resulting from the replacement of the eye's natural lens with a clear IOL.Missing: mechanism | Show results with:mechanism
  31. [31]
    SEEING BLUES ALL AROUND: A CASE OF PROPYLTHIOURACIL ...
    Jul 6, 2023 · Cyanopsia is a subjective symptom characterized by a bluish appearance of the overall visual field and has been reported among patients ...
  32. [32]
    [PDF] Blue Vision (Cyanopsia) Associated With TURP Syndrome: A Case ...
    There have been case reports of patients experiencing cyanopsia after cataract removal and intraocular lens implantation or with the use of phosphodiesterase 5 ...
  33. [33]
    A Look Ahead - American Academy of Ophthalmology
    Dec 1, 2023 · Traditionally, ocular oncologists rely on ophthalmologic features and imaging to make a differential diagnosis of common intraocular tumors ...<|control11|><|separator|>
  34. [34]
    Recent studies provide an updated clinical perspective on blue light ...
    This article evaluates the currently available published papers assessing the potential risks and benefits of blue light-filtering IOLs.
  35. [35]
    Adjusting to a sudden “aging” of the lens - PMC - NIH
    Following replacement of the lens with an intraocular lens (IOL), achromatic settings took months to return to near their pre-surgery settings. These slow ...
  36. [36]
    Visual function in patients with yellow tinted intraocular lenses ... - NIH
    The incidence of patients who noticed cyanopsia was significantly less in the yellow tinted IOL group than in the non‐tinted IOL group at 2 weeks after surgery ...Missing: post | Show results with:post
  37. [37]
    PDE5 Inhibitors May Create Unique Visual, Choroidal Changes
    Oct 27, 2023 · Sildenafil not only inhibits PDE5, the drug also weakly inhibits PDE6, but with an affinity of about one-tenth that of PDE5. Since PDE6 can be ...
  38. [38]
    Ultraviolet or blue-filtering intraocular lenses: what is the evidence?
    Jan 8, 2016 · It is widely known that a number of patients who receive clear lenses report that the visual scene has a blue tint (cyanopsia) post-operatively.
  39. [39]
    PDE5 inhibitors – pharmacology and clinical applications 20 years ...
    Since the discovery and introduction of sildenafil, inhibitors of PDE5 have been the first‐line therapy for erectile dysfunction (ED).
  40. [40]
    Phosphodiesterase Type 5 Inhibitors and Visual Side Effects
    The main reported side effects of PDE5i are headaches, dizziness, blushing, nasal congestion, dyspepsia, and visual changes. The most common visual side effects ...
  41. [41]
    Ocular Side Effects of Sildenafil That Persist Beyond 24 h-A Case ...
    This is a retrospective report of 17 cases in which patients experienced visual disturbances following 100-mg sildenafil use that persisted for ...
  42. [42]
    The evidence informing the surgeon's selection of intraocular lens ...
    Dec 9, 2016 · Although cyanopsia did occur more frequently in Group 1 than in Group 2 one month postoperatively (14.5 vs 4.9%; P=0.049), this difference was ...